Influenza A virus A/Tasmania/318/2025 CVR-351 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)

DB34093ApprovedVaccines

Influenza A virus A/Tasmania/318/2025 CVR-351 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) is a component of an inactivated influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses.

First approval: United States, 2026
Brand names: Flucelvax

What you can answer from here — as of October 19, 2026

3Marketed productsAcross 1 country and 3 labellers

Which companies are running trials of Influenza A virus A/Tasmania/318/2025 CVR-351 (H1N1) antigen (MDCK cell derived, propiolactone inactivated), in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account